Is further screening of men with baseline PSA < 1 ng ml-1 worthwhile? the discussion continues - Results of the Swiss ERSPC (Aarau)

International Journal of Cancer

Volumn 137, Issue 3, 2015, Pages 553-559

  Randazzo, Marco ^a,b   Beatrice, Josef ^a   Huber, Andreas ^a   Grobholz, Rainer ^a   Manka, Lukas ^c   Chun, Felix K ^d   Kluth, Luis A ^d   Wyler, Stephen F ^a   Recker, Franz ^a   Kwiatkowski, Maciej ^a,c  

^a CANTONAL HOSPITAL AARAU   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Academic Hospital Braunschweig   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

prostate cancer; prostate specific antigen; PSA below 1; screening interval

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE DURATION; EARLY DIAGNOSIS; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUMBER NEEDED TO SCREEN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROBABILITY; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; RISK FACTOR; SWITZERLAND; UNIVARIATE ANALYSIS; BLOOD; CANCER GRADING; INCIDENCE; MASS SCREENING; MIDDLE AGED; MORTALITY; PROSTATIC NEOPLASMS; REFERENCE VALUE; REPRODUCIBILITY;

AGED; EARLY DETECTION OF CANCER; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM GRADING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SWITZERLAND;

EID: 84929511083     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29420     Document Type: Article

References (26)

1. Center MM, Jemal A, Lortet-Tieulent J, et al., International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 1079-92.
2. Franks LM,. Latent carcinoma of the prostate. J Pathol Bacteriol 1954; 68: 603-16.
3. Heidenreich A, Bastian PJ, Bellmunt J, et al., European Association of UEAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014; 65: 124-37.
4. Loeb S, Bjurlin MA, Nicholson J, et al., Overdiagnosis and overtreatment of prostate cancer. Eur Urol 2014; 65: 1046-55.
5. Chou R, Croswell JM, Dana T, et al., Screening for prostate cancer: a review of the evidence for the US preventive services task force. Ann Inter Med 2011; 155: 762-71.
6. Fang J, Metter EJ, Landis P, et al., Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore longitudinal study of aging. Urology 2001; 58: 411-6.
7. Loeb S, Roehl KA, Antenor JA, et al., Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 2006; 67: 316-20.
8. Vickers AJ, Cronin AM, Bjork T, et al., Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. Br Med J 2010; 341: c4521
9. Lilja H, Cronin AM, Dahlin A, et al., Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 2011; 117: 1210-9.
10. Van der Meer S, Lowik SA, Hirdes WH, et al., Prostate specific antigen testing policy worldwide varies greatly and seems not to be in accordance with guidelines: a systematic review. BMC Fam Pract 2012; 13: 100.
11. Nordstrom T, Aly M, Clements MS, et al., Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, despite no recommendations for PSA screening: results from a population-based study, 2003-2011. Eur Urol 2013; 63: 419-25.
12. Randazzo M, Beatrice J, Huber A, et al,. A "PSA pyramid" for men with initial prostate-specific antigen
13. Roobol MJ, Roobol DW, Schroder FH,. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). Urology 2005; 65: 343-6.
14. Carlsson S, Assel M, Sjoberg D, et al., Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. Br Med J 2014; 348: g2296.
15. Kwiatkowski M, Huber A, Stamm B, et al., Features and preliminary results of prostate cancer screening in canton Aargau, Switzerland. BJU Int 2003; 92 (Suppl 2): 44-7.
16. -1. Combined with free-to-total ratio 20% or less: the Aarau experience. J Urol 2001; 166: 851-5.
17. D'Amico AV, Whittington R, Malkowicz SB, et al., Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74.
18. Howard K, Brenner AT, Lewis C, et al., A comparison of US and Australian men's values and preferences for PSA screening. BMC Health Serv Res 2013; 13: 388.
19. Thompson IM, Pauler DK, Goodman PJ, et al., Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-46.
20. Ross HM, Kryvenko ON, Cowan JE, et al., Do adenocarcinomas of the prostate with gleason score (GS)
21. Schroder FH, Hugosson J, Roobol MJ, et al., Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8.
22. Bul M, van Leeuwen PJ, Zhu X, et al., Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam. Eur Urol 2011; 59: 498-505.
23. Heidenreich A, Abrahamsson PA, Artibani W, et al., Early detection of prostate cancer: European association of urology recommendation. Eur Urol 2013; 64: 347-54.
24. Schroder FH, Hugosson J, Roobol MJ, et al., Screening and prostate cancer mortality: results of the European randomised study of screening for prostate cancer (ERSPC) at 13 years of follow-up. Lancet. 2014; 384: 2027-35.
25. Heijnsdijk EA, Wever EM, Auvinen A, et al., Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012; 367: 595-605.
26. Draisma G, Boer R, Otto SJ, et al., Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer. J Natl Cancer Inst 2003; 95: 868-78.